Trastuzumab Biosimilar Receives Positive Opinion From CHMP for European Approval

A marketing authorization for ABP 980, a biosimilar to trastuzumab (Herceptin), has been issued a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

Read full article (External website)

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply